Three months after Amgen washed its hands of the psoriasis drug brodalumab, its development partner AstraZeneca has found the exit door as well. The pharma giant auctioned off the Phase III-complete therapy to the wheeler dealers at Valeant in exchange for $100 million upfront, $170 million in pre-launch milestones and another $175 million in sales bonuses.
Sanofi is lending its weight to Google's ambitions in life sciences, joining the tech giant's recently unleashed healthcare division in hopes of developing new technologies to help manage diabetes.
Google is teaming up with French drugmaker Sanofi for a diabetes monitoring collaboration, furthering the tech giant's foray into medical devices and its commitment to developing innovative products for the disease.
The U.S. Department of Defense is sinking funds into a Silicon Valley initiative aimed at creating "flexible" electronics, furthering the agency's commitment to investing in innovative devices that could help soldiers on the battlefield.
Johnson & Johnson is joining forces with hardware manufacturing company PCH to launch a consumer-health focused hardware startup incubator, building on J&J's commitment to investing in early-stage companies to spur med tech innovation.
In an effort to widen the reach of its flu vaccines business--and to develop new vaccines on a familiar platform--Takeda has inked an agreement to expand its rights to the Vero cell technology platform for vaccines production from Florida's Nanotherapeutics, Inc.
Valneva has already made 5 deals this year licensing the use of its EB66 cell line to develop new vaccines, and now, it is adding two more to the list.
Chinese small-cap Lee's Pharm has signed CRO WuXi PharmaTech as its exclusive lab testing service to bolster the company's R&D program.
MorphoSys has moved to add targets for its immuno-oncology arsenal. The agreement sees MorphoSys gain access to tumor-associated peptides discovered by its compatriot Immatics Biotechnologies in exchange for some of its antibodies, with both companies paying out milestones as their respective programs advance.
Japan's R-Tech Ueno, which faced a clinical setback this year in ophthalmology even as it sought wider opportunities in the area, has seen U.S.-based Sucampo launch a tender for the firm valued at $278 million overall after the founders agreed to sell their holdings.